Clinical Trial Update: An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311 [Phase 2]

View source ↗

Summary

Extension study update for UB-311 (V203-AD) in Alzheimer's disease; Phase 2 trial terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• UB 311

Snippet

Sponsor: United Neuroscience Ltd. | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2020-12-17